Skip to main content
Clinical Trials/NCT06053177
NCT06053177
Active, not recruiting
Not Applicable

Primary Care Screening to Rapidly Detect Multi-organ Complications for People With Prediabetes and Type 2 Diabetes

University of Liverpool1 site in 1 country400 target enrollmentJanuary 25, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Type 2 Diabetes
Sponsor
University of Liverpool
Enrollment
400
Locations
1
Primary Endpoint
The prevalence of undiagnosed fatty liver disease with evidence of fibrosis, obstructive sleep apnoea and heart failure in people with type 2 diabetes and prediabetes
Status
Active, not recruiting
Last Updated
last year

Overview

Brief Summary

People with type 2 diabetes are at risk of complications linked with high blood sugars and these are monitored for in healthcare appointments. However, people with type 2 diabetes commonly suffer with additional health conditions that can affect the liver, heart and their breathing while sleeping. These conditions are thought to be caused by a similar underlying process that causes type 2 diabetes, as a result they are very common in people type 2 diabetes. Despite this they are not part of the routine health check for these people. Worryingly, current research suggests that the risk for developing these health problems, and direct complications of type 2 diabetes, can start at blood sugar levels below the threshold of type 2 diabetes. In a group of people said to have prediabetes. These people do not currently undergo annual healthcare appointments to monitor for these health complications or other linked health conditions.

This study aims to pilot a new style of clinic to address these issues. The investigators will perform a multi-morbidity assessment, where they will look for several different health problems at the same time. The investigators will be looking at health problems linked with high blood sugars, this will include problems with the liver, heart, nerves, eyes, and participants breathing overnight. They have developed a clinic visit which uses questionnaires, simple examination techniques and modern devices to try and identify these health problems.

An important part of healthcare is the burden it places on people with health problems, with this in mind the investigators will be giving the people involved in their study a voice to try and direct future research and healthcare, the investigators will ask them to provide feedback on their experience in taking part in the study and what their thoughts are in undergoing a longer but more comprehensive health appointment.

Registry
clinicaltrials.gov
Start Date
January 25, 2023
End Date
February 3, 2028
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Type 2 diabetes study group
  • Participants with a documented diagnosis of type 2 diabetes or HbA1c ≥48mmol/mol.
  • Age ≥18 years
  • Prediabetes study group
  • HbA1c 42 - 47 mmol/mol (inclusive) or enrolled in the diabetes prevention programme.
  • Age ≥18 years

Exclusion Criteria

  • Type 1, 3 or Maturity onset diabetes of the young.
  • Participants who are pregnant at the time of screening
  • Unable to give informed consent

Outcomes

Primary Outcomes

The prevalence of undiagnosed fatty liver disease with evidence of fibrosis, obstructive sleep apnoea and heart failure in people with type 2 diabetes and prediabetes

Time Frame: The majority of the data for this outcome measure is collected in a single study visit lasting approximatley 2 and a half hours. All data for this outcome would be collected within 4 weeks of participant enrollment.

Participants will complete two screening questionnaires for sleep apnoea, those identified as high risk for the condition will be given a home sleep study device to confirm or reject the diagnosis. All participants will have a fibroscan to look for the presence of fatty liver disease. Participants will be screened for heart failure, with those identified as high risk undergoing an echocardiogram to confirm or reject the diagnosis.

Secondary Outcomes

  • Peripheral neuropathy and cardiac autonomic dysfunction(The data for this outcome measure is collected in a single study visit lasting approximately 2 and a half hours.)
  • Multi-morbidity screening(The data for this outcome is collected as part of the primary study visit lasting approximately 2 and a half hours.)

Study Sites (1)

Loading locations...

Similar Trials